Pharmacokinetics and metabolism of oral doses of a 4′-methylthio derivative of propranolol in man

References

• Abernethy D. R., Greenblatt D. J. Impairment of antipyrine metabolism by low-dose oral contraceptive steroids. Clinical Pharmacology and Therapeutics 1981; 29: 106–110
   PubMed Web of Science ®Google Scholar
• Bai S. A., Easterling D. E., Wilson M. J., Walle U. K., Haney C. A., Peet N. P., Pruett J. K., Walle T. Pharmacokinetics and metabolism of a 4′-methylthio derivative of propranolol in the dog. Drug Metabolism and Disposition 1989; 17: 495–505
   Google Scholar
• Fagan T. C., Walle T., Oexmann M. J., Walle U. K., Bai S. A., Gaffney T. E. Increased clearance of propranolol and theophylline by high-protein compared with high carbohydrate diet. Clinical Pharmacology and Therapeutics 1987; 41: 402–406
   PubMed Web of Science ®Google Scholar
• Gransden D. F., Roth G. A., Takahashi I. T. The synthesis of 1-[(1-methylethyl)amino]-3-{[(4-methylthio)-1-naphthalenyl]oxy}-2-propanol hydrochloride-naphthalene-1-14C: 4′-Methylthiopropranolol. Journal of Labelled Compounds and Radiopharmaceuticals 1983; 20: 1073–1085
   Google Scholar
• Kornhauser D. M., Wood A. J. J., Vestal R. E., Wilkinson G. R., Branch R. A., Shand D. G. Biological determinants of propranolol disposition in man. Clinical Pharmacology and Therapeutics 1978; 23: 165–174
   PubMed Web of Science ®Google Scholar
• Lindner W. F. Tartaric acid moncesters of alkanolamines. 1987, U.S. Patent #4,652,672
   Google Scholar
• Melander A., Lalka D., McLean A. Influence of food on the presystemic metabolism of drugs. Pharmacology & Therapeutics 1988; 38: 253–267
   PubMedGoogle Scholar
• Nelson W. L., Powell M. L., Wennerstrom J. H. Absolute configuration of glycerol derivatives. 6. Cupra A circular dichroism spectra of 3-(aryloxy)-1-(alkylamino)-2-propanol β-adrenergic blocking agents. Journal of Organic Chemistry 1978; 43: 4907–4910
   Google Scholar
• Nimura N., Ogura H., Kinoshita T. Reversed-phase liquid chromatographic resolution of amino acid enantiomers by derivatization with 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl isothiocyanate. Journal of Chromatography 1980; 202: 375–379
   Web of Science ®Google Scholar
• Pruett J. K., Walle T. Correlation of tissue levels of propranolol (P) and methylthio propranolol (MTP) with effects on canine Purkinje fibers. Federation Proceedings 1980; 39: 1082
   Google Scholar
• Russell M. P., Privitera P. J., Walle T., Peet N. P., Halushka P. V., Gaffney T. E. Cardiovascular effects of a 4′-methylthio analog of propranolol. Journal of Pharmacology and Experimental Therapeutics 1981; 219: 685–690
   PubMed Web of Science ®Google Scholar
• Sager G., Nilsen O. G., Jacobsen S. Variable binding of propranolol in human serum. Biochemical Pharmacology 1979; 28: 905–911
   Google Scholar
• Schmid K. α-Acid glycoprotein. The Plasma Proteins: Structure, Function and Genetic Control, F. W. Putnam. Academic Press, New York 1975; Vol. 1: 183–228
   Google Scholar
• Sedman A. J., Gal J. Resolution of the enantiomers of propranolol and other beta-adrenergic antagonists by high-performance liquid chromatography,. Journal of Chromatography 1983; 278: 199–203
   Web of Science ®Google Scholar
• Shand D. G., Rangno R. E. The disposition of propranolol. I. Elimination during oral absorption in man. Pharmacology 1972; 7: 159–168
   PubMed Web of Science ®Google Scholar
• Shand D. G., Cotham R. H., Wilkinson G. R. Perfusion-limited effects of plasma drug binding on hepatic drug extraction. Life Sciences 1976; 19: 125–130
   PubMed Web of Science ®Google Scholar
• Sotaniemi E. A., Anttila M., Pelkonen R. O., Järvensivu P., Sundquist H. Plasma clearance of propranolol and sotalol and hepatic drug-metabolizing enzyme activity. Clinical Pharmacology and Therapeutics 1979; 26: 153–161
   PubMedGoogle Scholar
• Terao N., Shen D. D. Alterations in serum protein binding and pharmacokinetics of 1-propranolol in the rat elicited by the presence of an indwelling venous catheter. Journal of Pharmacology and Experimental Therapeutics 1983; 227: 369–375
   PubMedGoogle Scholar
• Walle T. 1-((1-Methylethyl)amino)-3-(((4-alkylthio)1-naphthalenyl)oxy)-2-propanol. 1982, U.S. Patent # 4,351,848
   Google Scholar
• Walle T., Morrison J., Walle K., Conradi E. Simultaneous determination of propranolol and 4′-hydroxypropranolol in plasma by mass fragmentography. Journal of Chromatography 1975; 114: 351–359
   PubMed Web of Science ®Google Scholar
• Walle T., Conradi E. C., Walle U. K., Fagan T. C., Gaffney T. E. The predictable relationship between plasma levels and dose during chronic propranolol therapy. Clinical Pharmacology and Therapeutics 1978; 24: 668–677
   Google Scholar
• Walle T., Fagan T. C., Walle U. K., Oexmann M. J., Conradi E. C., Gaffney T. E. Food-induced increase in propranolol bioavailability-relationship to protein and effects on metabolites. Clinical Pharmacology and Therapeutics 1981; 30: 790–795
   Web of Science ®Google Scholar
• Walle T., Oatis J. E., Jr., Walle U. K., Knapp D. R. New ring-hydroxylated metabolites of propranolol—species differences and stereospecific 7-hydroxylation. Drug Metabolism and Disposition 1982; 10: 122–127
   Google Scholar
• Walle T., Byington R. P., Furberg C. D., McIntyre K. M., Vokonas P. S. Biologic determinants of propranolol disposition: Results from 1308 patients in the Beta-blocker Heart Attack Trial. Clinical Pharmacology and Therapeutics 1985; 38: 509–518
   PubMedGoogle Scholar
• Walle T., Christ D. D., Walle U. K., Wilson M. J. Separation of the enantiomers of intact sulfate conjugates of adrenergic drugs by high-performance liquid chromatography after chiral derivatization. Journal of Chromatography 1985; 341: 213–216
   PubMedGoogle Scholar
• Walle T., Walle U. K., Olanoff L. S. Quantitative account of propranolol metabolism in urine of normal man. Drug Metabolism and Disposition 1985; 13: 204–209
   PubMed Web of Science ®Google Scholar
• Walle T., Walle U. K., Olanoff L. S., Conradi E. C. Partial metabolic clearances as determinants of the oral bioavailability of propranolol. British Journal of Clinical Pharmacology 1986; 22: 317–323
   Google Scholar
• Walle T., Webb J. G., Bagwell E. E., Walle U. K., Daniell H. B., Gaffney T. E. Stereoselective delivery and actions of beta receptor antagonists. Biochemical Pharmacology 1988; 37: 115–124
   Google Scholar
• Walle T., Walle U. K., Cowart T. D., Conradi E. C. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clinical Pharmacology and Therapeutics 1989; 46: 257–263
   PubMed Web of Science ®Google Scholar
• Wilson M. J., Ballard K. D., Walle T. Preparative resolution of the enantiomers of the β-blocking drug atenolol by chiral derivatization and high-performance liquid chromatography. Journal of Chromatography 1988; 431: 222–227
   PubMed Web of Science ®Google Scholar
• Wilson T. W., Firor W. B, Johnson G. E., Holmes G. I., Tsianco M. C., Huber P. B., Davies R. O. Timolol and propranolol: Bioavailability, plasma concentrations, and beta blockade. Clinical Pharmacology and Therapeutics 1982; 32: 676–685
   PubMed Web of Science ®Google Scholar
• Wood A. J. J., Carr K., Vestal R. E., Belcher S., Wilkinson G. R., Shand D. G. Direct measurement of propranolol bioavailability during accumulation to steady-state. British Journal of Clinical Pharmacology 1978; 6: 345–350
   PubMed Web of Science ®Google Scholar
• Yasuhara M., Fujiwara J., Kitade S., Katayama H., Okumura K., Hori R. Effect of altered plasma protein binding on pharmacokinetics and pharmacodynamics of propranolol in rats after surgery: Role of alpha-1-acid glycoprotein. Journal of Pharmacology and Experimental Therapeutics 1985; 235: 513–520
   PubMed Web of Science ®Google Scholar